Developments in the therapeutic use of erythropoiesis stimulating agents.
about
Alternative procedures for reducing allogeneic blood transfusion in elective orthopedic surgery.Comparison of Neurite Outgrowth Induced by Erythropoietin (EPO) and Carbamylated Erythropoietin (CEPO) in Hippocampal Neural Progenitor Cells.Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal.Emerging technologies in the delivery of erythropoietin for therapeutics.Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia.Designer protein delivery: From natural to engineered affinity-controlled release systems.SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control.Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple SclerosisAbsorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in ratsEffects of erythropoietin abuse on exercise performance.The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers.Comments on Lundby et al.'s "testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing". Problems associated with current anti-doping testing: is quality assessment a reliable solution?The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.Generation of transgenic chickens expressing the human erythropoietin (hEPO) gene in an oviduct-specific manner: Production of transgenic chicken eggs containing human erythropoietin in egg whites.
P2860
Q34079843-61D85781-DBF0-47A0-AA31-9BD35CA8A67CQ36166115-5A9EB69A-B2F3-4ADF-B14B-C4E888F50808Q37358669-2CF56C00-17CE-4B1D-B907-B2E89DA8C190Q37524229-BDE3DC6E-4D6A-4617-B2CF-9B5840475B21Q37646523-25F250D9-C4EE-47B6-BC1D-2E3410E7ABB6Q37779100-CEC7D51B-0219-4260-96EE-8F224253588BQ38293159-CDD83A4E-F661-444D-8E9B-E4F7563E6D6CQ40015078-BF1C5495-092E-4745-BFFC-67782FF85B01Q41173431-FADF6118-4511-45CA-83F4-66B42ABB537EQ42257325-459B42DC-F68D-4483-9D2E-AA91D4E2F43AQ48347751-98E8E76C-E5AB-4C4A-BC51-0FF3CA9A0910Q50522400-327ECF53-D474-4E5F-8171-3705E996329AQ51782444-AF37F2B9-E87C-4093-BB58-EF932639DF8BQ53120576-7E449213-14B2-4249-AAB6-548BE0499315Q55252265-DCF41B86-5226-48A3-A468-E228A96B4C65
P2860
Developments in the therapeutic use of erythropoiesis stimulating agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developments in the therapeutic use of erythropoiesis stimulating agents.
@en
Developments in the therapeutic use of erythropoiesis stimulating agents.
@nl
type
label
Developments in the therapeutic use of erythropoiesis stimulating agents.
@en
Developments in the therapeutic use of erythropoiesis stimulating agents.
@nl
prefLabel
Developments in the therapeutic use of erythropoiesis stimulating agents.
@en
Developments in the therapeutic use of erythropoiesis stimulating agents.
@nl
P2860
P1476
Developments in the therapeutic use of erythropoiesis stimulating agents.
@en
P2093
Wolfgang Jelkmann
P2860
P304
P356
10.1111/J.1365-2141.2007.06948.X
P407
P577
2008-05-01T00:00:00Z